earnings
confidence high
sentiment negative
materiality 0.75
Harvard Bioscience Q1 net loss $50.3M includes $48M goodwill impairment; guides Q2 revenue $18-20M
HARVARD BIOSCIENCE INC
2025-Q1 EPS reported
-$1.14
revenue$21,774,000
- Revenue $21.8M vs $24.5M YoY (-11%); net loss $(50.3)M vs $(4.7)M, including $48.0M goodwill impairment.
- Gross margin 56.0% vs 60.3% YoY; Adjusted EBITDA $0.8M vs $1.6M YoY.
- Q2 2025 guidance: revenue $18M-$20M, gross margin 55%-57%.
- CEO cites NIH funding uncertainty, tariff impact on China sales; cost savings ~$1M/qtr starting Q2.